Department of Neurology & Co-innovation Center of Neuroregeneration, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Department of Neurology, Suzhou Municipal Hospital of Anhui, Suzhou, Anhui, China.
Mov Disord. 2019 Jan;34(1):138-141. doi: 10.1002/mds.27569. Epub 2018 Nov 28.
Lymphocyte activation gene-3 (LAG-3) could mediate pathological α-synuclein transmission in neurodegeneration and may be involved in the pathogenesis of Parkinson's disease (PD). The aim of the present study was to explore soluble LAG-3 (sLAG-3) as a potential diagnostic biomarker for PD.
Serum sLAG-3 concentrations were measured by a quantitative ELISA for patients with PD, essential tremor (ET) and age- and sex-matched controls. The relationships between sLAG-3 and clinical phenotype were assessed via correlation analysis and logistic regression.
Serum sLAG-3 levels in patients with PD were significantly higher than those in ET patients and age- and sex-matched controls. The area under the curve of serum sLAG-3 in differentiating PD from age- and sex-matched controls was 0.82. Serum sLAG-3 was associated with non-motor symptoms and excessive daytime sleep.
sLAG-3 is a candidate novel biomarker for PD. © 2018 International Parkinson and Movement Disorder Society.
淋巴细胞激活基因 3（LAG-3）可介导神经退行性变中病理性 α-突触核蛋白的传递，可能与帕金森病（PD）的发病机制有关。本研究旨在探讨可溶性 LAG-3（sLAG-3）作为 PD 的潜在诊断生物标志物。
采用定量 ELISA 法检测 PD、特发性震颤（ET）患者和年龄、性别匹配的对照组血清 sLAG-3 浓度。通过相关性分析和逻辑回归评估 sLAG-3 与临床表型之间的关系。
PD 患者血清 sLAG-3 水平明显高于 ET 患者和年龄、性别匹配的对照组。血清 sLAG-3 区分 PD 与年龄、性别匹配对照组的曲线下面积为 0.82。血清 sLAG-3 与非运动症状和日间过度嗜睡有关。
sLAG-3 是 PD 的候选新型生物标志物。
